The estimated Net Worth of Richard I Eisenstadt is at least $886 Tisíc dollars as of 30 January 2024. Mr. Eisenstadt owns over 9,275 units of Neos Therapeutics Inc stock worth over $48,951 and over the last 9 years he sold NEOS stock worth over $0. In addition, he makes $837,031 as Chief Financial Officer a Treasurer at Neos Therapeutics Inc.
Sign up
Mr. Eisenstadt NEOS stock SEC Form 4 insiders trading
Richard has made over 6 trades of the Neos Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 9,275 units of NEOS stock worth $10,666 on 30 January 2024.
The largest trade he's ever made was exercising 12,500 units of Neos Therapeutics Inc stock on 29 December 2023 worth over $14,375. On average, Richard trades about 2,408 units every 123 days since 2015. As of 30 January 2024 he still owns at least 42,566 units of Neos Therapeutics Inc stock.
You can see the complete history of Mr. Eisenstadt stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Richard Eisenstadt biography
Richard Eisenstadt serves as Chief Financial Officer, Treasurer of the Company. Mr. Eisenstadt has served as our Chief Financial Officer since May 2014. Prior to joining us, he served as Chief Financial Officer of ArborGen Inc. from January 2013 to May 2014, and as Vice President of Finance and Chief Financial Officer of Tranzyme, Inc., now part of Mallinckrodt Pharmaceuticals (NYSE: MNK) from June 2003 to December 2012. He previously held financial leadership positions at Cogent Neuroscience, Inc. and Nimbus CD International, Inc. Mr. Eisenstadt received his M.B.A. from James Madison University and his B.A. in Economics from the University of North Carolina, Chapel Hill.
What is the salary of Richard Eisenstadt?
As the Chief Financial Officer a Treasurer of Neos Therapeutics Inc, the total compensation of Richard Eisenstadt at Neos Therapeutics Inc is $837,031. There are 1 executives at Neos Therapeutics Inc getting paid more, with Gerald McLaughlin having the highest compensation of $1,399,430.
How old is Richard Eisenstadt?
Richard Eisenstadt is 61, he's been the Chief Financial Officer a Treasurer of Neos Therapeutics Inc since 2018. There are 1 older and 8 younger executives at Neos Therapeutics Inc. The oldest executive at Neos Therapeutics Inc is Alan Heller, 66, who is the Independent Chairman of the Board.
What's Richard Eisenstadt's mailing address?
Richard's mailing address filed with the SEC is 2940 N State Hwy 360 Service Rd E #400, Grand Prairie, TX 75050, USA.
Insiders trading at Neos Therapeutics Inc
Over the last 9 years, insiders at Neos Therapeutics Inc have traded over $796,275 worth of Neos Therapeutics Inc stock and bought 558,630 units worth $7,201,055 . The most active insiders traders include Jack W Schuler, James E Deerfield Mgmt L.P.... a Bryant Fong. On average, Neos Therapeutics Inc executives and independent directors trade stock every 69 days with the average trade being worth of $42,698. The most recent stock trade was executed by Richard I Eisenstadt on 12 December 2018, trading 5,000 units of NEOS stock currently worth $10,800.
What does Neos Therapeutics Inc's logo look like?
Complete history of Mr. Eisenstadt stock trades at Altimmune Inc, Neos Therapeutics Inc a Aytu BioPharma Inc
Neos Therapeutics Inc executives and stock owners
Neos Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Gerald McLaughlin,
President, Chief Executive Officer, Director -
Richard Eisenstadt,
Chief Financial Officer, Treasurer -
John Limongelli,
Senior Vice President, General Counsel and Corporate Secretary -
Alan Heller,
Independent Chairman of the Board -
Linda Szyper,
Independent Director -
John Schmid,
Independent Director -
Gregory Robitaille,
Independent Director -
Bryant Fong,
Independent Director -
James Robinson,
Independent Director -
Beth Hecht,
Independent Director -
Vipin K Garg,
President, CEO & Director -
Juergen Martens,
Chief Tech/Operations Officer -
Thomas P Mc Donnell,
Chief Commercial Officer -
Paul R Edick,
Director -
Partners 2007, L.P.Presidio...,
-
Dorothy Engelking,
VP of Regulatory Affairs -
Mark Tengler,
Chief Technology Officer -
Ralph Essex Capital Corp Ia...,
-
Andrew G Delaware Street Ca...,
-
Jack W Schuler,
10% owner -
Venture Assoicates Ii Llcbu...,
-
James E Deerfield Mgmt L.P....,